multiple sclerosis news - Search News

Sanofi, Multiple Sclerosis

Bloomberg L.P. · 2d

Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.

BioTechniques · 2d

Biomarkers for predicting multiple sclerosis progression identified

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the development of more personalized treatment strategies.

Benzinga.com · 2d

Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows

Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed increased disability improvement,

Sanofi's tolebrutinib drug delays progressive MS by 31% in trial

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.

The Globe and Mail · 2d

New multiple sclerosis drug by Sanofi delays progressive form of disease by 31 per cent in trial

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end of MS pill Aubagio’s patent protection

FierceBiotech2d

Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

MedPage Today1d

Women With MS Less Likely to Receive Treatment Than Men

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

Multiple Sclerosis News Today3d

ECTRIMS 2024: High-dose vitamin D can help delay progression to MS

High-dose cholecalciferol (vitamin D) is safe and can nearly double the time it takes for clinically isolated syndrome to ...

Medpage Today on MSN5d

Higher Comorbidity Burden in Multiple Sclerosis Tied to Worse Outcomes

Higher comorbidity burden among people with multiple sclerosis (MS) was associated with worse clinical outcomes, pooled trial ...

PHILADELPHIA.Today on MSN2d

Local Multiple Sclerosis Advocate Honored With State Citation

Bucks County resident Joseph “Smiley” Terinoni was recently presented with a citation from the Pennsylvania House of ...

Does Multiple Sclerosis Protect Against Alzheimer's?

Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...

4don MSN

California’s cap on health care costs is the nation’s strongest. But will patients notice?

Vickie Villegas had to pay $3,000 out-of-pocket every time she was treated for multiple sclerosis, a disease that attacks the ...

3don MSN

Key biomarkers identified for predicting disability progression in multiple sclerosis

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

High-Dose Vitamin D Linked to Lower Disease Activity in CIS

Vitamin D is linked to a 34% reduction in the relative risk for disease activity in patients with clinically isolated ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results